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| INTRODUCTION
Therapeutic options for managing hyperglycaemia in subjects with type 2 diabetes (T2DM) have increased markedly over the last decades, and there are now 8 major classes, in addition to insulin (Table 1) . While the glucose-lowering activities of drugs such as the biguanides, sulphonlylureas and thiazolidinediones were discovered serendipitously without initially understanding exactly how they worked, newer classes such as dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like peptide (GLP)-1 receptor agonists and sodium glucose-linked transporter (SGLT)-2 inhibitors were discovered using rational drug design, based on a prior knowledge of the target mechanism. This has helped to minimize any off-target adverse events, while any side effects are usually minor (and largely predictable). Abbreviations: ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; DKD, diabetic kidney disease; DPP-4, dipeptidyl peptidase-4; ESRD, end-stage renal disease; FDA, Food and Drug Administration; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HR, hazard ratio; MACE, major adverse cardiovascular events; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RCT, randomized controlled trial; SDF-1α, stromal cell-derived factor 1α; SGLT-2, sodium-glucose cotransporter-2; T2DM, type 2 diabetes mellitus glucagon secretion), whereby glycaemic excursions are reduced. GLP-1 additionally delays gastric emptying and has satiety effects, leading to reduced food intake and loss of body weight. The actions of inhibitors are believed to be exerted primarily through enhancing levels of the intact (active) form of endogenous GLP-1, although other substrates, including GIP may also contribute.
1 Their development as therapeutic agents proceeded rapidly; from the initial hypothesis published in 1995, 2 via publication of the first randomized controlled trial (RCT) showing glucose lowering in T2DM, 3 to the launch of the first DPP-4 inhibitor took only 11 years, and worldwide, at least 11 DPP-4
inhibitors have now been approved for management of T2DM. 4, 5 Numerous studies have shown that DPP-4 inhibitors are effective antihyperglycaemic agents which lower HbA1c levels with broadly similar efficacy to the more traditional oral antidiabetic drugs (eg, metformin, sulphonylureas, thiazolidinediones), but which generally are associated with fewer adverse side effects, 6 thereby placing them among preferred second-line options in many treatment guidelines. 7, 8 Focus in a number of clinical trials has therefore shifted from simply looking at efficacy towards exploring how best to optimize their usage and further evaluating their safety. 19 In a 24-week study in T2DM patients, the deterioration of diastolic dysfunction (E/e', assessed using echocardiography) was attenuated by the addition of sitagliptin compared to conventional treatment alone, although glycaemic control and blood pressure were similar in both arms of the study, and neither cardiac structure nor systolic function were affected. 20 On this background, it had therefore been anticipated that the DPP-4 inhibitor CV safety outcome trials might also reveal a positive effect on CV risk reduction. That this was not seen might be due to a number of factors, notable among which is the difference in patient populations. By definition, the CV safety outcome studies were conducted in patients at high CV risk, with the majority having established CVD (Table 2) , a group which typically accounts for a minority (~20%) of patients with T2DM. 32 Similarly, the smaller placebocontrolled SITAGRAMI trial, comparing the effects of progenitor cell therapy with the combination of sitagliptin and granulocyte-colony stimulating factor, which, like the CV outcome trials, also failed to show any beneficial effect on cardiac function or clinical events, was also carried out in patients with a history of CVD (successfully revascularized acute myocardial infarction). 33 Moreover, these patients, as well as those in the larger CV outcome trials were well treated for co-morbidities, with high proportions on statins, aspirin and antihypertensive agents (Table 2) Such speculation would be in line both with the neutral effects seen in the CV safety outcome studies in subjects in whom the majority had already experienced at least 1 CV event, [9] [10] [11] as well as with the reports that the number of CV events may have been lower in the relatively healthier phase 3 trial populations.
14, [21] [22] [23] [24] [25] While the large outcome trials, which together have included almost 50 000 individuals, are providing reassuring evidence concerning the CV safety of the DPP-4 inhibitors, they also provide huge databases which can be explored to further investigate safety and tolerability of DPP-4 inhibitors.
| Heart failure
One unexpected finding to come out of the DPP-4 inhibitor CV safety trials was the observation that the risk of hospitalization for heart failure (a predefined component of the secondary endpoint in SAVOR-TIMI), albeit low, was modestly increased in the SAVOR-TIMI trial (3.5% with saxagliptin vs 2.8% with placebo; HR = 1.27), although this was not associated with any increase in mortality. 9 Further analysis indicated that the increased risk became evident during the first 12 months, stabilizing thereafter, with event rates overall being highest in those patients who had a history of heart failure, impaired renal function or elevated baseline levels of N-terminal pro B-type natriuretic peptide (ie, those already at a greater risk of heart failure). 34 Hospitalization for heart failure was not part of the primary or secondary endpoints in the EXAMINE trial (but was an adjudicated component of exploratory composite endpoints), and given the findings from SAVOR-TIMI, a retrospective posthoc analysis was carried out. This revealed a numerically greater (non-significant) increase in hospital admission for heart failure with alogliptin (3.1%) compared to placebo (2.9%), but composite events of CV death and hospital admission for heart failure were not increased, irrespective of heart failure history or baseline B-type natriuretic peptide levels. Although the event rates were higher in patients with previous heart failure, alogliptin was not associated with more new heart failure hospitalization events or with worsening of heart failure outcomes. 35 TECOS also revealed no sign of any increase in hospitalization related to heart failure with sitagliptin (3.1% in both arms of the trial), 11 with further analysis showing no difference in the time to the first event nor in the numbers with recurrent events of heart failure hospitalization. Moreover, as in EXAMINE, outcomes were not different between the sitagliptin and placebo arms, even in those patients with pre-existing heart failure. for heart failure seen in SAVOR-TIMI and the non-significant trend in EXAMINE, the FDA has added a warning concerning heart failure for patients at risk of heart failure to the DPP-4 inhibitor labels. HbA1c as well as overall tolerability (Table 4) being similar to what is seen in patients without renal disease.
The large CV safety outcome studies also included large numbers of patients with impaired renal function, and analyses of the cohorts with chronic kidney disease (CKD) in TECOS and SAVOR-TIMI clearly showed a correlation between poorer renal function and increasing numbers of CV, renal and hypoglycaemic events, as expected. [48] [49] [50] However, with the exception of hospitalization for heart failure in SAVOR-TIMI (which was higher in the saxagliptin arm), overall event rates in the CKD cohort, although greater in number, were generally not different between the DPP-4 inhibitor and the placebo arms of the trials, 48, 50 reflecting the findings in the trial populations as a whole, 9, 11 and indicating that the presence of kidney disease per se did not differentially influence outcomes in the 2 arms of the trials. Moreover, a specific analysis of renal events in SAVOR-TIMI revealed no adverse effects of DPP-4 inhibition with saxagliptin on renal safety outcomes. 51 
| Potential renoprotection
Diabetic nephropathy is a major cause of CKD, and it is associated with worse CV outcomes and increased mortality. Accordingly, focus is placed upon both the early detection of diabetic kidney disease (DKD, by monitoring surrogate markers such as the progression of albuminuria and the decline in glomerular filtration rate [GFR]), and the treatment of renal risk factors, including hyperglycaemia, in order to prevent and/or reduce DKD and improve outcomes. 52 It is therefore noteworthy that in addition to providing safe and effective glycaemic control in renally impaired patients, there is some evidence to suggest that DPP-4 inhibitors could have some beneficial renal effects unrelated to their effects on glycaemic control (Figure 1 ). In rodents, a diuretic and natriuretic effect has been reported, [53] [54] [55] and DPP-4 inhibition has been associated with reductions in urinary albuminuria. 56, 57 While glomerular filtration may be modestly increased, 53, 56 it has also been suggested that DPP-4 inhibition can reduce glomerular hyperfiltration, 53,55 thereby leading to amelioration of experimental diabetes-induced renal haemodynamic changes. Furthermore, DPP-4 inhibition also appears to be associated with some improvement in histopathological changes in the diabetic kidney, with reports that glomerulosclerosis and tubulo-interstitial fibrosis are reduced and podocyte loss is attenuated in diabetic rodent models. [55] [56] [57] [58] [59] Intriguingly, some of these effects are still present even in the absence of GLP-1 receptor signalling, 53, 54 and it has been suggested that another DPP-4 substrate, stromal cell-derived factor 1α (SDF-1α), may be involved in mediating some of the renal effects of DPP-4 inhibition. 55 Data from clinical studies investigating whether DPP-4 inhibitors alter the progression of diabetic nephropathy damage are still relatively sparse, but where it has been measured, GFR appears not to be altered. Thus, in studies in overweight patients with T2DM and normal renal function, 12 weeks treatment with the DPP-4 inhibitor DEACONsitagliptin (or the GLP-1 agonist liraglutide) had no effect on renal haemodynamic variables or GFR compared to placebo, 60 while neither renal plasma flow nor GFR was affected by 4 weeks treatment with linagliptin. 61 A similar lack of effect on GFR was also noted in MARLINA-T2D, a 24-week study specifically designed to evaluate any renal effects of DPP-4 inhibition with linagliptin compared to placebo in individuals at early stages of DKD. 62 Moreover, there was no impact of sitagliptin 40 or vildagliptin 42 on GFR, even when renal function was already moderately/severely impaired. Likewise, in the longer duration CV safety outcome studies, neither alogliptin 10 nor saxagliptin 9,51 had any effect on GFR compared to placebo, while in TECOS, although GFR was modestly lower in the sitagliptin arm, the rate of decline was similar in both arms of the trial as a whole 11, 49 (but interestingly, a sub-group analysis revealed no decline in GFR in the sitagliptin cohort with CKD in TECOS 50 ). Of note, a recent mechanistic study has reported that, compared with placebo, acute and chronic (1 month) DPP-4 inhibition with sitagliptin in patients with T2DM stimulated natriuresis in the distal, rather than the proximal, tubule, via a mechanism said to involve enhancement of levels of SDF-1α, 63 in line with some of the animal data mentioned above. 55 Distal tubule natruiresis should not affect tubuloglomerular feedback, and accordingly, in that study, as in the larger RCTs mentioned above, no effect on GFR or other renal haemodynamic parameters was observed. 63 While GFR and renal haemodynamics are apparently unaffected by DPP-4 inhibition in the clinical trials, the data regarding effects on albuminuria are less clear. Thus, SAVOR-TIMI indicated overall reductions in albuminuria with some reversal of its progression (improvement in and/or less deterioration in urinary albumin-to-creatinine ratio [ACR] categories) with saxagliptin compared to placebo treatment, 9,48,51 which was more evident in patients with normal/ mildly impaired renal function or moderate to severe renal impairment. 48 Similar results were seen in a placebo-controlled RCT in patients with moderate to severe renal impairment, showing that 12 weeks treatment with gemigliptin ameliorated albuminuria, with effects being more marked in those patients with macro-albuminuria. 64 Pooled analyses of large phase 3 RCT data with linagliptin have also suggested a beneficial effect on kidney disease endpoints, including albuminuria, 65 while small RCTs, uncontrolled single-arm studies or observational studies have indicated improvements in albuminuria with sitagliptin, 66,67 alogliptin 68 and vildagliptin. 69 However, in TECOS, in the subsets where it was measured, urinary ACR was marginally reduced, 49 but the incidence of micro-albuminuria was similar in the sitagliptin and placebo arms of the trial. 11 Likewise, in the study in overweight patients with T2DM and normal renal function, urinary ACR and other markers of renal damage were not altered by 12 weeks of sitagliptin treatment, 60 while in MARLINA-T2D, although glycaemic control was significantly improved, the addition of linagliptin to standard care had no effect on albuminuria. 62 The reasons for these discrepancies are at present unclear. It has, however, been speculated that longer duration of treatment may be required in order to see any renal benefits, since the available data suggest that they may be more likely to be related to reduction in other renal risk factors (eg, glycaemic control, blood pressure, body weight) and/or to reduction in interstitial fibrosis (as seen in animal studies) rather than changes in renal haemodynamics. 60, 62 The larger longer duration CARMELINA study ( 
| COMBINATIONS OF DPP-INHIBITORS AND INSULIN

| Addition to stable insulin therapy
Insulin therapy is often used when oral agents no longer provide adequate glycaemic control, but despite this, many patients are still not able to reach glycaemic targets. For some, the complexity associated with using insulin, together with the fear of hypoglycaemia and the desire not to gain weight, may result in a delay in starting insulin treatment or hinder intensification of pre-existing insulin therapy. In addition to being simple to use, weight-neutral oral agents with a mechanism of action that is complementary to that of insulin, one particular appeal of combining DPP-4 inhibitors with insulin lies with the fact that not only do they not unduly increase the risk of hypoglycaemia (because their insulinotropic effect is glucose-dependent), but they may exert a protective effect against hypoglycaemia via their effects on the α-cell. Thus, in 4-week cross-over studies in drugnaïve 70 or insulin-treated 71 T2DM patients, the DPP-4 inhibitor vildagliptin enhanced α-cell responsiveness to glucose compared to placebo, suppressing glucagon when glucose levels were elevated but enhancing 70 or sustaining 71 showing a benefit in terms of HbA1c reduction. [72] [73] [74] [75] [76] [77] [78] Moreover, despite the lower glucose levels, the risk of hypoglycaemia was generally not increased 73, 75, 76, 78 (unless the protocol specified that ) or may even be lower, 72, 77 and overall, severe hypoglycaemia episodes were rare.
Furthermore, not only was overall glycaemic control improved but, in studies where it has been examined, the combination of DPP-4 inhibition with insulin seemed to be associated with improvements in glycaemic variability compared to placebo, 79 with particularly nocturnal glycaemic variability being reduced. 80, 81 In longer duration studies of up to 1 year, the beneficial effect on glycaemic control was maintained, with more patients reaching target HbA1c levels without increased risk of hypoglycaemia or weight gain. [82] [83] [84] [85] This may be related to an insulin-sparing effect when a DPP-4 inhibitor is added, allowing the insulin dose to be reduced, as seen in some studies, 82, 83 perhaps associated with overall improvements in α-and β-cell function (reductions in post-prandial glucagon levels, increased insulin secretory rates) which have been seen compared to placebo. 84, 85 In the above studies, the additional efficacy obtained by the addition of DPP-4 inhibition to insulin therapy appeared to be independent of the type of insulin used, and was evident in both younger (<65 years) and older (≥65 years) subjects, as well as in elderly individuals (≥75 years). 86 Of particular note, these observations also extend to T2DM patients with CKD, where insulin therapy is widely used, and where other drugs may be inappropriate or contra-indicated (Table 3) . As described above, DPP-4 inhibitors have been widely studied in patients with impaired renal function, many of whom were treated with insulin [41] [42] [43] [44] 47, 62 (Table 4 ). In specific analyses of the sub-groups on insulin, the addition of a DPP-4 inhibitor improved HbA1c levels irrespective of renal function without increasing the incidence or severity of hypoglycaemia or the number of renal adverse events.
87,88
| Use when intensification of therapy is required
While it might be expected that initiation of an additional antihyperglycaemic agent to a stable insulin dose would result in additional glucose lowering, rather fewer studies have specifically investigated the combination of DPP-4 inhibition and insulin when therapy needs intensifying.
In one relatively small (n = 124), open-label study, patients on a stable insulin dose were randomized to the addition of sitagliptin or to up-titration of insulin (insulin dose increased by 25% by week 24), revealing that better glycaemic control was attained with less hypoglycaemia and no weight gain, 89 although it has been argued that the degree of insulin titration may have been more conservative than seen in clinical practice. 90 In a larger, blinded study in subjects with unsatisfactory control on insulin therapy (with or without metformin), the addition of a DPP-4 inhibitor prior to intensification of basal insulin therapy (targeting fasting plasma glucose between 4.0 and 5.6 mmol/L) was associated with a smaller increase in the daily insulin dose compared to placebo, and fewer patients experienced hypoglycaemia. 91 Glucose control improved in both arms but to a greater extent in the patients receiving the DPP-4 inhibitor. Accordingly, the combination of DPP-4 inhibition with insulin may be beneficial compared to an insulin-only regimen in helping patients reach glycaemic targets.
Because T2DM is a progressive disease, the majority of patients will, however, require therapy intensification, and many will ultimately require insulin once glycaemic control can no longer be adequately maintained with oral agents alone. This raises a question of whether it is better to retain or replace a DPP-4 inhibitor when insulin is initiated. This was addressed in a 24-week study in patients with inadequate control on dual therapy with sitagliptin and metformin.
Compared to discontinuing the DPP-4 inhibitor and intensifying therapy by adding biphasic insulin aspart in a twice-daily regimen, similar glycaemic control with less hypoglycaemia and no weight gain could be obtained with less insulin (insulin aspart used once daily) if sitagliptin was retained. 92 Moreover, although some of the benefit on weight was reduced, glycaemic control was even better if twice-daily insulin aspart was added while still continuing with the DPP-4 inhibitor, and the risk of hypoglycaemia was not increased. inhibition plus basal insulin combination, and with less weight gain than seen in the subjects on the twice-daily premixed insulin regimen. 93 The question of when to initiate insulin therapy was examined in a third study, in which inadequately controlled insulin-naïve patients on metformin (AE another oral agent), were randomized to therapy intensification with a basal insulin-based regimen combined with DPP-4 inhibition (insulin detemir + sitagliptin added to existing metformin therapy, any other oral agent discontinued) or to intensification of oral therapy (addition of sitagliptin to on-going metformin AE sulphonylurea). 94 This study showed that the combination of DPP-4 inhibition with insulin resulted in better glycaemic control with improved glucose profiles, a low incidence of hypoglycaemia and no adverse effects on weight, giving some support that, for some patients at least, earlier initiation of insulin may be preferential to intensification of oral agents.
| FUTURE POSSIBILITIES FOR DPP-4 INHIBITORS?
5.1 | In-hospital management of hyperglycaemia Dysregulated glycaemic control occurs relatively frequently in patients admitted to hospital with non-critical illness or following surgery, and it is known to be associated with longer hospital stays and worse outcomes. 95 However, because oral agents are not recommended in such patients, control of hyperglycaemia relies heavily on insulin-based regimens, which can be both complicated and time consuming to manage. 95 Given the benign side effect profile and good tolerability of DPP-4 inhibitors, their applicability for most patients, and that they are oral agents, their use for management of DEACONhyperglycaemia in the hospital setting is being studied. In a pilot study, the use of sitagliptin with or without low-dose insulin glargine was compared to a basal-bolus insulin regimen (insulin glargine once daily plus rapid-acting insulin lispro before each meal), in general medicine and surgery patients with T2DM; supplemental doses of insulin lispro were allowed as required. Glycaemic control was improved to a similar extent, but less insulin (total daily dose and number of injections) was required in the sitagliptin arms of the trial.
Hypoglycaemic events and the length of hospital stay were also similar between the treatments, indicating the feasibility of using DPP-4 inhibition in this setting. 96 These results were confirmed in a larger study, again showing that a sitaglitin/basal insulin regimen was as effective in lowering glucose levels as basal-bolus insulin, with equivalent improvements in hyperglyaemia and no difference in the amount or severity of hypoglycaemia. 97 As in the previous study, the total daily insulin dose and number of injections were reduced in the sitagliptin group (driven by a reduction in prandial insulin requirements), and there were no differences in either the duration of hospital stay or in complications. 97 Glucose control with saxagliptin has also been compared against basal-bolus insulin (both with correctional insulin aspart before each meal and bedtime as needed) in noncritically ill hospitalized patients. As in the previous 2 studies, indices of overall glycaemic control were broadly similar (although there was a downward trend in blood glucose levels over the 6-day study period with saxagliptin), with less insulin being needed in the DPP-4 inhibitor group. Glycaemic variability (assessed by continuous glucose monitoring) was also reduced. 98 Together, these studies suggest that DPP-4 inhibition (with or without basal insulin) may be a viable, easier to implement alternative to basal-bolus insulin for managing hyperglycaemia in non-critically ill hospitalized patients.
| Use in T2DM patients with fatty liver disease
T2DM is often associated with non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH) or cirrhosis, and it is in itself a CV risk factor. 99 in overweight T2DM patients. As expected, both incretin therapies improved glycaemic control compared to placebo, and although hepatic steatosis was reduced, this occurred to a similar extent in all 3 groups, and there were no differences in hepatic fibrosis scores between treatments. 101 Similar results were seen in 24-week RCTs in pre-diabetic and T2DM patients with NAFLD 102 and in T2DM subjects with biopsy-confirmed NASH, 103 showing again no difference between sitagliptin and placebo in either liver fat content or hepatic fibrosis. 102 In contrast, a 27% decrease in intra-hepatic triglycerides was seen after 6 months treatment of well-controlled T2DM patients with vildagliptin compared to placebo, which was independent of weight change or peripheral insulin sensitivity, 104 while in another study, sitagliptin and glimepiride had similar effects to improve glycaemic control after 24 weeks, but a reduction in intrahepatic lipids (−15%) was seen only with the DPP-4 inhibitor. 105 Vildagliptin has also been reported to improve fatty liver grading (assessed by ultrasound) in non-diabetic patients with fatty liver after 12 weeks of treatment, whereas no effects were noted with placebo. 106 While these studies all indicate that DPP-4 inhibition is safe and can improve glycaemic control in patients with NAFLD or NASH, further, longer term studies are required in order to resolve whether or not DPP-4 inhibitors have any effect on the progression of fatty liver disease.
| CONCLUSIONS
In the 15 years since the first clinical study, 3 showing an antihyperglycaemic effect of DPP-4 inhibition in patients with T2DM, was published, a wealth of data has come from numerous RCTs.
These have uniformly shown that DPP-4 inhibitors are effective and well-tolerated in all patients with T2DM. They are not associated with excess hypoglycaemia or weight gain, or with increased CV risk.
Their mechanism of action is such that they work in a manner that is complimentary to both the more traditional therapies (Table 1) inhibitors extends to the older subjects. 10, 108, 109 The glycaemic efficacy and safety of DPP-4 inhibition in T2DM
patients is now well documented, and research focus is now beginning to shift towards exploring other opportunities for optimizing treatment using DPP-4 inhibitors. In addition to their potential renoprotective effects, possible benefit for in-hospital management of T2DM patient and use in patients with NAFLD, as discussed above, the utility of DPP-4 inhibition in other diverse conditions, such as, for 
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